A key player behind 2 multibillion-dollar biotech M&A deals is back in the startup business
Pratik Shah and Aseem Ansari have snared a $45 million launch round for Design Therapeutics, a San Diego-based outfit that is focused on degenerative diseases linked to nucleotide repeat expansions. The biotech has identified a lead program that zeroes in on Friedreich’s ataxia with discovery efforts underway for other diseases.
You might remember that Shah was CEO of Auspex for 2 years, before Teva scooped it up for $3.5 billion in 2015. The investor was also chairman at Synthorx, another San Diego company that Sanofi recently picked up for $2.5 billion.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
